Lamictal

Lamictal

lamotrigine

Manufacturer:

GlaxoSmithKline

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Lamotrigine
Indications/Uses
Adjunctive or monotherapy in treatment of epilepsy for partial & generalized seizures, including tonic-clonic seizures & seizures associated w/ Lennox-Gastaut syndrome. Bipolar disorder: Prevention of mood episodes predominantly by preventing depressive episode.
Dosage/Direction for Use
Adult >16 yr Epilepsy monotherapy Initially 25 mg once daily for 2 wk, followed by 50 mg once daily for 2 wk. May be increased to max: 50-100 mg every 1-2 wk. Maintenance: 100-200 mg once daily or as 2 divided doses. Adult >12 yr Add-on therapy w/ valproate Initially 25 mg every alternate day for 2 wk, followed by 25 mg once daily for 2 wk. May be increased to max: 25-50 mg every 1-2 wk. Maintenance: 100-200 mg once daily or in 2 divided doses. Add-on therapy w/ antiepileptics or other medications inducing lamotrigine glucuronidation Initially 50 mg once daily for 2 wk, followed by 100 mg daily in 2 divided doses for 2 wk. May be increased to max: 100 mg every 1-2 wk. Maintenance: 200-400 mg daily in 2 divided doses. Add-on therapy w/ drugs that do not significantly inhibit or induce lamotrigine glucuronidation Initially 25 mg once daily for 2 wk, followed by 50 mg once daily for 2 wk. May be increased to max: 50-100 mg every 1-2 wk. Maintenance: 100-200 mg once daily or as 2 divided doses. Childn 2-12 yr Add-on therapy w/ valproate Initially 0.15 mg/kg once daily for 2 wk, followed by 0.3 mg/kg once daily for 2 wk. May be increased to max: 0.3 mg/kg every 1-2 wk. Maintenance: 1-5 mg/kg once daily or in 2 divided doses. Max: 200 mg daily. Add-on therapy w/ antiepileptics or other medications inducing lamotrigine glucuronidation Initially 0.6 mg/kg daily in 2 divided doses for 2 wk, followed by 1.2 mg/kg daily in 2 divided doses for 2 wk. May be increased to max: 1.2 mg/kg every 1-2 wk. Maintenance: 5-15 mg/kg daily in 2 divided doses. Max: 400 mg daily. Add-on therapy w/ drugs that do not significantly inhibit or induce lamotrigine glucuronidation Initially 0.3 mg/kg once daily or in 2 divided doses for 2 wk, followed by 0.6 mg/kg once daily or in 2 divided doses for 2 wk. May be increased to max: 0.6 mg/kg every 1-2 wk. Maintenance: 1-10 mg/kg once daily or in 2 divided doses. Max: 200 mg daily. Adult ≥18 yr Bipolar disorder adjunct therapy w/ valproate Initially 25 mg every alternate day for 2 wk, followed by 25 mg once daily for 2 wk. May be increased to 50 mg once daily or in 2 divided doses for 1 wk. Usual target dose: 100 mg once daily or in 2 divided doses, may be increased to max: 200 mg daily. Adjunct therapy w/ phenytoin, carbamazepine, phenobarb, primidone & other drugs inducing lamotrigine glucuronidation Initially 50 mg once daily for 2 wk, followed by 100 mg daily in 2 divided doses for 2 wk. May be increased to 200 mg daily as 2 divided doses for 1 wk, then further increased to 300 mg daily for 1 wk. Usual target dose: 400 mg daily in 2 divided doses for 1 wk. Monotherapy or adjunct therapy w/ drugs that do not significantly induce or inhibit lamotrigine glucuronidation Initially 25 mg once daily for 2 wk, followed by 50 mg once daily or in 2 divided doses for 2 wk. May be increased to 100 mg daily for 1 wk. Usual target dose: 200 mg once daily or as 2 divided doses.
Administration
May be taken with or without food: Tab: Swallow whole, do not chew/crush. Dispersible tab: May be chewed/dispersed in a small vol of water or swallowed whole w/ a little water.
Contraindications
Special Precautions
History of allergy or rash to other antiepileptic drugs. Not to be restarted in patients who have discontinued due to rash or aseptic meningitis associated w/ prior treament. Not to be used for bipolar disorder in childn & adolescents <18 yr. Haemophagocytic lymphohistiocytosis; patients w/ Brugada syndrome. Monitor for clinical worsening, suicidal ideation/behaviour, thoughts or unusual changes in behaviour. Avoid abrupt w/drawal. Long-term use. Not recommended in co-administration w/ OCT2 substrates eg, dofetilide. Not to be administered in patients currently being treated w/ other prep containing lamotrigine. Concomitant use w/ hormonal contraceptives. May affect ability to drive & use machines. Renal failure. Hepatic impairment. Pregnancy & lactation. Major depressive & other psychiatric disorders in childn & adolescents <18 yr. Childn <2 yr w/ epilepsy.
Adverse Reactions
Skin rash; headache, somnolence, ataxia, dizziness; diplopia, blurred vision; nausea, vomiting. Aggression, irritability; insomnia, tremor, nystagmus, agitation; diarrhoea; tiredness; arthralgia; pain, back pain.
Drug Interactions
Inhibited glucuronidation by valproate. Induced glucuronidation by carbamazepine, phenytoin, primidone, phenobarb, rifampicin, lopinavir/ritonavir/atazanavir, ethinylestradiol/levonorgestrel combination. Increased topiramate conc. Reduced AUC & Cmax w/ OCs. False +ve reading for phencyclidine.
MIMS Class
Anticonvulsants
ATC Classification
N03AX09 - lamotrigine ; Belongs to the class of other antiepileptics.
Presentation/Packing
Form
Lamictal dispersible tab 25 mg
Packing/Price
30's
Form
Lamictal dispersible tab 5 mg
Packing/Price
30's
Form
Lamictal tab 100 mg
Packing/Price
30's
Form
Lamictal tab 50 mg
Packing/Price
30's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in